Kadmon Holdings Inc (NYSE:KDMN) has been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.95.
Several equities analysts have commented on the company. ValuEngine raised Kadmon from a “sell” rating to a “hold” rating in a research report on Wednesday. Cantor Fitzgerald assumed coverage on Kadmon in a research report on Thursday, September 5th. They issued an “overweight” rating and a $8.00 price objective on the stock. Finally, Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, October 9th.
Several institutional investors and hedge funds have recently bought and sold shares of KDMN. Meeder Asset Management Inc. grew its position in shares of Kadmon by 736.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 9,955 shares of the company’s stock worth $25,000 after buying an additional 8,765 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new position in Kadmon in the second quarter valued at about $27,000. Parametric Portfolio Associates LLC purchased a new position in Kadmon in the second quarter valued at about $30,000. California Public Employees Retirement System purchased a new position in Kadmon in the third quarter valued at about $56,000. Finally, Capital Investment Advisors LLC raised its position in Kadmon by 134.5% in the second quarter. Capital Investment Advisors LLC now owns 28,815 shares of the company’s stock valued at $59,000 after purchasing an additional 16,525 shares during the period. 76.65% of the stock is currently owned by institutional investors and hedge funds.
Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.03). The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.46 million. Kadmon had a negative net margin of 3,974.23% and a negative return on equity of 96.96%. On average, equities research analysts forecast that Kadmon will post -0.54 EPS for the current fiscal year.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
See Also: Buy-Side Analysts
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.